Drug Profile
Research programme: obesity therapeutic - MannKind Corporation
Alternative Names: MKC 180Latest Information Update: 21 Apr 2011
Price :
$50
*
At a glance
- Originator MannKind Corporation
- Class Hormones; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Feb 2011 Discontinued - Preclinical for Obesity in USA (Inhalation)